[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364132-105":59,"doc-detail-364132-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","landscape-of-acquired-resistance-alterations-in-gastrointestinal-malignancies-after-genomically-targeted-therapy","Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy","","Liquid biopsy using circulating tumor DNA (ctDNA) was evaluated to characterize acquired genomic resistance in gastrointestinal (GI) cancers treated with targeted therapies. Patients with GI malignancies receiving standard-of-care or investigational agents targeting EGFR, HER2, FGFR, MET, KRAS, or BRAF for at least 60 days underwent baseline comprehensive profiling and post-progression ctDNA sequencing. Among 106 patients, resistance-associated alterations were detected in 53%, with heterogeneous patterns and multiple concurrent events. Resistance drivers included on-target and bypass mechanisms, with RAS alterations prominent for bypass resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/landscape-of-acquired-resistance-alterations-in-gastrointestinal-malignancies-after-genomically-targeted-therapy/364132/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/landscape-of-acquired-resistance-alterations-in-gastrointestinal-malignancies-after-genomically-targeted-therapy/364132.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was acquired resistance assessed in GI malignancies in this study?","Question",{"text":112,"@type":113},"The study used ctDNA analysis from liquid biopsies, comparing baseline comprehensive genomic profiling with post-progression ctDNA sequencing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What proportion of patients showed resistance-associated alterations?",{"text":117,"@type":113},"At least one putative resistance-associated alteration was detected in ctDNA in 53% of the 106 included patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the major categories of resistance mechanisms observed?",{"text":121,"@type":113},"Resistance alterations were classified as either bypass (activating alternative oncogenic pathways, commonly MAPK signaling) or on-target (secondary changes within the drug target). RAS alterations were a key mechanism of bypass resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364132,1790634000,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Original Article  \nLandscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy  \nPriyadarshini Pathak\\# , Bennett Caughey\\# ^, Haley Barnes, Matthew Strickland, Elizabeth Walsh, Jeffrey Clark, Lawrence Blazkowsky, Aparna Parikh, Colin Weekes, Samuel Klempner, Ryan Corcoran  \nDivision of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA  \nContributions: (I) Conception and design: P Pathak, B Caughey, H Barnes, R Corcoran; (II) Administrative support: H Barnes; (III) Provision of study materials or patients: P Pathak, B Caughey, M Strickland, E Walsh, J Clark, L Blazkowsky, A Parikh, C Weekes, S Klempner, R Corcoran; (IV) Collection and assembly of data: P Pathak, B Caughey, H Barnes, R Corcoran; (V) Data analysis and interpretation: P Pathak, B Caughey, H Barnes, R Corcoran; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \n\\#These authors contributed equally to this work.  \nCorrespondence to: Ryan Corcoran, MD, PhD. Division of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical  \nSchool, 149 13th St., 7th Floor, Boston, MA 02129, USA. Email: [rbcorcoran@mgb.org](rbcorcoran@mgb.org).  \nBackground: Targeted therapies directed at specific genomic alterations have transformed the management of gastrointestinal (GI) cancers; however, acquired resistance remains inevitable. Circulating tumor DNA (ctDNA) analysis via liquid biopsy provides a non-invasive approach to characterize genomic mechanisms of resistance. We therefore evaluated patterns of acquired genomic resistance in patients with GI cancers  \ntreated with targeted therapies.  \nMethods: Patients with GI cancers treated with standard of care or investigational therapies targeting EGFR, HER2, FGFR, MET, KRAS, BRAF for at least 60 days who underwent both baseline comprehensive  \ngenomic profiling and post-progression ctDNA sequencing were retrospectively evaluated.  \nResults: Of 106 patients meeting inclusion criteria, 45 had biliary tract cancer (BTC), 42 colorectal cancer (CRC), and 19 other GI malignancies. At least one putative resistance-associated alteration was detected in ctDNA in 53% of cases. Resistance patterns were heterogeneous with 47% showing no detectable alterations and 33% harboring ≥2 resistance alterations. Among 164 total alterations, the majority were single nucleotide variants (82%), followed by amplifications (17%) . Overall, 48% were classified as ‘bypass’alterations—activating alternative oncogenic pathways, most commonly MAPK signaling—while 52% were‘on-target’ alterations involving secondary changes within the drug target. RAS alterations represented a key mechanism of bypass resistance, accounting for 28% of all resistance alterations. Interestingly, in CRC, bypass alterations predominated (69%), whereas in BTCs, on-target alterations were more frequent (61%) .  \nConclusions: Liquid biopsies frequently identify acquired resistance following targeted therapy across GI cancers, often revealing multiple concurrent alterations. Patterns of resistance varied by tumor type, with both on-target and bypass mechanisms observed. These findings highlight common themes of resistance and support the growing clinical role of ctDNA analysis in defining resistance and guiding management in GI  \nmalignancies  \nKeywords: Gastrointestinal malignancies; precision oncology; acquired resistance  \nSubmitted Dec 20, 2025. Accepted for publication May 15, 2026. Published online Jun 24, 2026.  \ndoi: 10.21037/jgo-2025-1-1025  \nView this article at: [https://dx.doi.org/10.21037/jgo-2025-1-1025](https://dx.doi.org/10.21037/jgo-2025-1-1025)  \n^ ORCID: 0000-0002-3970-1651.  \n© AME Publishing Company. J Gastrointest Oncol 2026;17(4):243 | [https://dx.doi.org/10.21037/jgo-2025-1-1025](https://dx.doi.org/10.21037/jgo-2025-1-1025)  \nPage 2 of 11 Pathak et al. Landscape of acquired resistance in GI can","cbCaij8pt5wyMait","https://ap.wps.com/l/cbCaij8pt5wyMait","pdf",1516239,11,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Introduction\n## Highlight box\n## What is known and what is new?\n## What is the implication, and what should change now?","[{\"question\":\"How was acquired resistance assessed in GI malignancies in this study?\",\"answer\":\"The study used ctDNA analysis from liquid biopsies, comparing baseline comprehensive genomic profiling with post-progression ctDNA sequencing.\"},{\"question\":\"What proportion of patients showed resistance-associated alterations?\",\"answer\":\"At least one putative resistance-associated alteration was detected in ctDNA in 53% of the 106 included patients.\"},{\"question\":\"What were the major categories of resistance mechanisms observed?\",\"answer\":\"Resistance alterations were classified as either bypass (activating alternative oncogenic pathways, commonly MAPK signaling) or on-target (secondary changes within the drug target). RAS alterations were a key mechanism of bypass resistance.\"}]","Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy | PDF",1790155878,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92a0422a81cee1dab929e179a60089c9.webp",983,1287,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a986ff196eaaf8d2371a0ffafebb189.webp",982,1286,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72d804b9ecee53c5bb6d5a50efdba500.webp",981,1284,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/884564881b4327ecc24cf231bf1a3f0b.webp",980,1283]